Biomarker for the Detection and Monitoring of Bladder Cancer

Description:

The inventors have developed a biomarker application based on thromboxane receptor β (TPβ), which identifies patients with various stages of bladder cancers (invasive, superficial, or metastatic). TPβ proteins are overexpressed in common bladder tumor tissue but not normal human cells. Human urine samples of patients positive for various degrees of bladder cancer confirm sensitivity approaching 93%, with 100% specificity. The detection of these proteins provide a novel, non-invasive early diagnostic method and for follow up monitoring in case of recurrence.

 

Overview:

Bladder cancer is the fifth most common cancer in U.S. (4.6%). When detected early stage, it has a 94% survival rate. Survival rate drops to 46% after spreading to surrounding region, and declines to 6% after metastases. The gold standard for diagnosing via cystoscopy, however this is invasive, costly and is limited to interpretation bias. Other diagnostic assays, such as cystoscopy and fluorescent in situ hybridization (FISH), have limited sensitivity (50-70%). Improved sensitivity and specificity for bladder cancer would significantly increase patient survival. Also given a high recurrence rate, an easy to administer follow up procedure would be an effective clinical application in healthcare.

 

Advantages: Highly specific and selective early detection and progressive monitoring of bladder cancer

Applications: Bladder Cancer

Key Words: Bladder cancer, urine analysis, assay, specificity, selectivity, diagnostic, thromboxane receptor

 

Publications: Moussa, Omar, et al. “Urinary thromboxane B2 and thromboxane receptors in bladder cancer: opportunity for detection and monitoring.”  Prostaglandins Other Lipid Mediators 2011 Nov; 96(1-4):41-4.

 

Moussa, Omar, et al. “Novel role of thromboxane receptors beta isoform in bladder cancer pathogenesis.”  Cancer Research 2008 Jun 1; 68(11):4097-104.

 

 

Inventors: O. Moussa, D. Watson, P. Halushka

Patent Status: US Patent 8,101,371

MUSC-FRD Technology ID: P0804

Patent Information:
Category(s):
Diagnostic
For Information, Contact:
Scott Davis
Sr Licensing Manager
MUSC Foundation for Research Development
843-876-1900
davissco@musc.edu
Inventors:
Omar Moussa
Dennis Watson
Perry Halushka
Keywords:
cancer
diagnostic
genitourinary
© 2017. All Rights Reserved. Powered by Inteum